S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Real Problem With "Made in America" Lithium (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
How to Invest in AI's Fast-Growing Market (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Real Problem With "Made in America" Lithium (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
How to Invest in AI's Fast-Growing Market (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Real Problem With "Made in America" Lithium (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
How to Invest in AI's Fast-Growing Market (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Real Problem With "Made in America" Lithium (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
How to Invest in AI's Fast-Growing Market (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
How to Invest in Specialty Retail Stores
NASDAQ:DCTH

Delcath Systems (DCTH) Stock Forecast, Price & News

$7.51
-0.45 (-5.65%)
(As of 06/1/2023 ET)
Compare
Today's Range
$7.21
$7.99
50-Day Range
$4.84
$7.96
52-Week Range
$2.34
$7.99
Volume
223,986 shs
Average Volume
55,565 shs
Market Capitalization
$79.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.67

Delcath Systems MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
121.9% Upside
$16.67 Price Target
Short Interest
Bearish
4.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.15mentions of Delcath Systems in the last 14 days
Based on 11 Articles This Week
Insider Trading
Acquiring Shares
$95,087 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.40) to ($1.24) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

1409th out of 1,980 stocks

Surgical & Medical Instruments Industry

143rd out of 200 stocks


DCTH stock logo

About Delcath Systems (NASDAQ:DCTH) Stock

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Receive DCTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter.

DCTH Stock News Headlines

The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
Delcath Systems Q1 2023 Earnings Preview
Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Update
H.C. Wainwright Reaffirms Their Buy Rating on Delcath Systems (DCTH)
Why Delcath Systems Shares Are Jumping Today
See More Headlines

DCTH Price History

DCTH Company Calendar

Last Earnings
5/22/2023
Today
6/02/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DCTH
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.67
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+121.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-36,510,000.00
Net Margins
-1,212.45%
Pretax Margin
-1,242.19%

Debt

Sales & Book Value

Annual Sales
$2.72 million
Book Value
($1.23) per share

Miscellaneous

Free Float
8,841,000
Market Cap
$79.76 million
Optionable
Not Optionable
Beta
0.86

Key Executives

  • Mr. Gerard J. Michel MBAMr. Gerard J. Michel MBA (Age 60)
    MS, CEO & Director
    Comp: $683.82k
  • Mr. John Purpura M.S.Mr. John Purpura M.S. (Age 62)
    Chief Operating Officer
    Comp: $482.56k
  • Dr. Johnny John M.D. (Age 59)
    Sr. VP Clinical Devel. & Medical Affairs
    Comp: $383.63k
  • Mr. Anthony C. Dias (Age 56)
    VP of Fin.
  • Mr. David Hoffman
    Gen. Counsel, Corp. Sec. & Chief Compliance Officer
  • Mr. Robin Wagge
    Sr. VP of Rubenstein Associates
  • Mr. Kevin Muir
    VP of Commercial Operations













DCTH Stock - Frequently Asked Questions

Should I buy or sell Delcath Systems stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DCTH shares.
View DCTH analyst ratings
or view top-rated stocks.

What is Delcath Systems' stock price forecast for 2023?

2 analysts have issued 1 year target prices for Delcath Systems' shares. Their DCTH share price forecasts range from $14.00 to $19.00. On average, they predict the company's stock price to reach $16.67 in the next year. This suggests a possible upside of 121.9% from the stock's current price.
View analysts price targets for DCTH
or view top-rated stocks among Wall Street analysts.

How have DCTH shares performed in 2023?

Delcath Systems' stock was trading at $3.60 at the beginning of the year. Since then, DCTH stock has increased by 108.6% and is now trading at $7.51.
View the best growth stocks for 2023 here
.

Are investors shorting Delcath Systems?

Delcath Systems saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 457,600 shares, an increase of 7.9% from the April 30th total of 424,200 shares. Based on an average daily trading volume, of 44,400 shares, the days-to-cover ratio is currently 10.3 days.
View Delcath Systems' Short Interest
.

When is Delcath Systems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our DCTH earnings forecast
.

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (NASDAQ:DCTH) released its quarterly earnings results on Monday, May, 22nd. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by $0.20. The firm had revenue of $0.60 million for the quarter. Delcath Systems had a negative trailing twelve-month return on equity of 1,396.28% and a negative net margin of 1,212.45%.

When did Delcath Systems' stock split?

Shares of Delcath Systems reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What guidance has Delcath Systems issued on next quarter's earnings?

Delcath Systems updated its first quarter 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $600.00K-$600.00K, compared to the consensus revenue estimate of $770.00K.

What is Delcath Systems' stock symbol?

Delcath Systems trades on the NASDAQ under the ticker symbol "DCTH."

Who are Delcath Systems' major shareholders?

Delcath Systems' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.59%), Advisors Capital Management LLC (0.27%), BlackRock Inc. (0.16%), Renaissance Technologies LLC (0.11%) and Tower Research Capital LLC TRC (0.04%). Insiders that own company stock include Ernest C Garcia II, Gerard J Michel, Gil Aharon, John Purpura, Rosalind Advisors, Inc and Steven A J Salamon.
View institutional ownership trends
.

How do I buy shares of Delcath Systems?

Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Delcath Systems' stock price today?

One share of DCTH stock can currently be purchased for approximately $7.51.

How much money does Delcath Systems make?

Delcath Systems (NASDAQ:DCTH) has a market capitalization of $79.76 million and generates $2.72 million in revenue each year. The company earns $-36,510,000.00 in net income (profit) each year or ($3.73) on an earnings per share basis.

How can I contact Delcath Systems?

Delcath Systems' mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The official website for the company is delcath.com. The company can be reached via phone at 212-489-2100, via email at investorrelations@delcath.com, or via fax at 212-489-2102.

This page (NASDAQ:DCTH) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -